Tachikawa Kanako, Yamazaki Miwa, Michigami Toshimi
Department of Bone and Mineral Research, Research Institute, Osaka Women's and Children's Hospital, Osaka Prefectural Hospital Organization, Osaka, Japan.
Clin Pediatr Endocrinol. 2023;32(3):180-187. doi: 10.1297/cpe.2023-0019. Epub 2023 May 6.
Hypophosphatasia (HPP) is caused by inactivating variants of the gene, which encodes tissue non-specific alkaline phosphatase (TNSALP). Among the six subtypes of HPP, childhood HPP presents after 6 months and before 18 yr of age, and is inherited in both autosomal dominant and autosomal recessive manners. Patients with childhood HPP have variable symptoms, including rickets-like bone changes, low bone mineral density (BMD), short stature, muscle weakness, craniosynostosis, and premature loss of deciduous teeth. Here, we describe a 7-yr-old boy with childhood HPP who showed short stature, impaired ossification of the carpal bones, and low BMD. Genetic testing identified a novel heterozygous 51-bp in-frame deletion in the gene (c.1482_1532del51), leading to the lack of 17 amino acids between Gly495 and Leu511 (p.Gly495_Leu511del). transfection experiments revealed the loss of enzymatic activity and the dominant-negative effect of the TNSALP[p.Gly495_Leu511del] variant; thus, the patient was diagnosed as having autosomal dominant HPP. The TNSALP[p.Gly495_Leu511del] variant was localized to the plasma membrane as was the wild-type TNSALP (TNSALP[WT]): however, co-immunoprecipitation experiments suggested a reduced dimerization between TNSALP[p.Gly495_Leu511del] and TNSALP[WT]. This case expands the variable clinical manifestation of childhood HPP and sheds light on the molecular bases underlying the dominant-negative effects of some TNSALP variants.
低磷性佝偻病(HPP)由编码组织非特异性碱性磷酸酶(TNSALP)的基因的失活变体引起。在HPP的六种亚型中,儿童期HPP在6个月至18岁之间出现,以常染色体显性和常染色体隐性两种方式遗传。儿童期HPP患者有多种症状,包括佝偻病样骨改变、低骨矿物质密度(BMD)、身材矮小、肌肉无力、颅缝早闭和乳牙过早脱落。在此,我们描述了一名患有儿童期HPP的7岁男孩,他表现出身材矮小、腕骨骨化受损和低BMD。基因检测在该基因中发现了一个新的杂合51 bp框内缺失(c.1482_1532del51),导致甘氨酸495和亮氨酸511之间缺少17个氨基酸(p.Gly495_Leu511del)。转染实验揭示了TNSALP[p.Gly495_Leu511del]变体的酶活性丧失和显性负效应;因此,该患者被诊断为患有常染色体显性HPP。TNSALP[p.Gly495_Leu511del]变体与野生型TNSALP(TNSALP[WT])一样定位于质膜;然而,免疫共沉淀实验表明TNSALP[p.Gly495_Leu511del]和TNSALP[WT]之间的二聚化减少。该病例扩展了儿童期HPP的可变临床表现,并揭示了一些TNSALP变体显性负效应的分子基础。